SARS-CoV-2, a spillover from animals to man, a spillback from man to animals and… what next?
Professor Giovanni Di Guardo discusses the relationship between animals and humans in regards to the transmission of SARS-CoV-2.
List view / Grid view
Articles
Expert view: Analytical power tool opens upstream bioprocessing bottlenecks for better antibody screening
The Octet® systems provide broad applications in high throughput to help bispecific and multi-specific antibody discovery.
Under the microscope: Searching for optimised drugs: combining AI with human expertise
Applying artificial intelligence (AI) to small molecule drug discovery can provide a more rapid and cost‑effective route to discovering drug candidates. Here, Martin Redhead, Head of Quantitative Pharmacology at Exscientia, discusses the role of AI in drug discovery, the processes involved and how it can be used to address the…
Expert view: Increasing the efficiency of biologics development: the secret is precise and reliable stability characterisation of candidate molecules
Biologics are becoming increasingly important for the treatment of a wide variety of diseases, with more biologics receiving regulatory approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and entering the clinic every year.
NGS In-Depth Focus 2020
In this NGS In-Depth Focus: how next-generation sequencing (NGS) enables rapid detection of viruses and a novel NGS platform advancing genomics research.
Assays In-Depth Focus 2020
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
Targets In-Depth Focus 2020
This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently identified interactions between the SARS-CoV-2 Spike protein and host epithelial cells could be used in the development of COVID-19 therapeutics.
Antibodies In-Depth Focus 2020
Included in this in-depth focus are articles on antibody therapeutics to treat COVID-19, how AAV antibodies can be neutralised, the role of antibodies in cancer therapy and bispecific antibodies for immuno-oncology drugs.
Drug Target Review – Issue 3 2020
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
Translating novel drug success in animals to humans
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
Coronavirus update: COVID-19 vaccine pre-clinical developments
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.
Five developments in oncology targets
Drug Target Review explores some of the newest oncologic drug targets, including those for glioblastoma, lung cancer and breast cancer.
A circuit involved in itching: from skin to sensory neurons
Dr Santosh Mishra and Srisruti Bontala explain how they discovered a new cutaneous-nerve pathway for allergic itch in atopic dermatitis.
Five of the most recent microscopy developments
Drug Target Review highlights five of the latest imaging advancements in the field of microscopy.
